Myeloid engraftment enhancement after autologous peripheral blood progenitor cell transplant

This indication refers to the therapeutic acceleration of hematopoietic recovery following high-dose myeloablative chemotherapy or conditioning regimens and subsequent autologous peripheral blood progenitor cell transplantation It addresses the period of severe, post-transplant marrow aplasia, specifically targeting the hematopoietic and immune systems in patients undergoing cellular therapy for hematologic malignancies or solid tumors

This indication refers to the therapeutic acceleration of hematopoietic recovery following high-dose myeloablative chemotherapy or conditioning regimens and subsequent autologous peripheral blood progenitor cell transplantation It addresses the period of severe, post-transplant marrow aplasia, specifically targeting the hematopoietic and immune systems in patients undergoing cellular therapy for hematologic malignancies or solid tumors

Pathophysiologically, the clinical state is characterized by profound pancytopenia, marked by prolonged, life-threatening neutropenia that leaves the patient highly susceptible to severe infections and sepsis Enhancement of myeloid engraftment aims to stimulate the proliferation, differentiation, and homing of infused progenitor cells to expedite absolute neutrophil count recovery (typically sustained at or above 500 cells/µL) and shorten the duration of critical immune vulnerability

Enhancement of myeloid engraftment aims to stimulate the proliferation, differentiation, and homing of infused progenitor cells to expedite absolute neutrophil count recovery (typically sustained at or above 500 cells/µL) and shorten the duration of critical immune vulnerability